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Essential tremor is one of the most frequent movement disorders of
humans and can be associated with substantial disability. Some but
not all persons with essential tremor develop signs of Parkinson
disease, and the relationship between the conditions has not been
clear. In a six-generation consanguineous Turkish kindred with both
essential tremor and Parkinson disease, we carried out whole exome
sequencing and pedigree analysis, identifying HTRA2 p.G399S as
the allele likely responsible for both conditions. Essential tremor
was present in persons either heterozygous or homozygous for this
allele. Homozygosity was associated with earlier age at onset of
tremor (P < 0.0001), more severe postural tremor (P < 0.0001), and
more severe kinetic tremor (P = 0.0019). Homozygotes, but not
heterozygotes, developed Parkinson signs in the middle age. Among
population controls from the same Anatolian region as the family,
frequency of HTRA2 p.G399S was 0.0027, slightly lower than other
populations. HTRA2 encodes a mitochondrial serine protease. Loss
of function of HtrA2was previously shown to lead to parkinsonian
features in motor neuron degeneration (mnd2) mice. HTRA2 p.
G399S was previously shown to lead to mitochondrial dysfunction,
altered mitochondrial morphology, and decreased protease activ-
ity, but epidemiologic studies of an association between HTRA2
and Parkinson disease yielded conflicting results. Our results sug-
gest that in some families, HTRA2 p.G399S is responsible for hered-
itary essential tremor and that homozygotes for this allele develop
Parkinson disease. This hypothesis has implications for understand-
ing the pathogenesis of essential tremor and its relationship to
Parkinson disease.
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Essential tremor is one of the most frequent movement dis-orders in humans (1). It is characterized primarily by postural
or kinetic tremor of the arms and hands, but head, legs, voice, and
other regions of the body may also be affected (2). The worldwide
prevalence is 0.9%, increasing to more than 4% in elderly pop-
ulations (1). Familial essential tremor is genetically heterogeneous.
Genetic linkage studies of multiply affected families revealed three
genomic regions segregating with the condition, on chromosomes
3q13 [ETM1; Online Mendelian Inheritance in Man (OMIM)
190300], 2p22-24 (ETM2; OMIM 602134), and 6p23 (ETM3;
OMIM 611456) (3–5). No clearly causal mutations have been
identified in these regions, although the common variant DRD3
p.S9G in the ETM1 region has been proposed as a risk factor and
HS1BP3 p.A265G in the ETM2 region appeared in two multiply
affected families (6, 7). Genomewide association studies of es-
sential tremor reported associations with common variants in an
intron of LINGO1 and in an intron of SLC1A2 (8–10). Recently,
DNAJC13 p.N855S, which had been identified in Parkinson dis-
ease patients, was also found in two unrelated patients with es-
sential tremor (11). Nonsense mutation p.Q290X in the RNA-
binding protein FUS was identified by whole exome sequencing in
a large family with essential tremor (ETM4; OMIM 614782) (12).
Screening other subjects with essential tremor for FUS revealed
two rare missense variants, suggesting that mutations in FUS ex-
plain a subset of cases with the condition (13, 14).
In this study, we examined a six-generation family segregat-
ing essential tremor, and in multiple relatives, essential tremor
as a feature of Parkinson disease. We carried out whole exome
sequencing of genomic DNA from three severely affected
family members and subsequent pedigree analysis to identify
the genetic basis of essential tremor and Parkinson disease in
the family.
Results
Clinical Features. The ET-1 family is from central Anatolia, where
consanguineous marriages are common practice. Ancestors of
the extended family have lived in the same area for more than
400 y. Essential tremor is known to have segregated in the family
for generations. For this study, 24 individuals from the family
were clinically assessed (Fig. 1). Diagnosis of essential tremor
was based on criteria of the consensus statement on tremor of
the movement disorder society (15). Diagnosis of Parkinson
disease required presence of bradykinesia plus at least one of
muscular rigidity, resting tremor, or postural instability (16).
Significance
Essential tremor is one of the most frequent movement
disorders of humans, but its causes remain largely unknown.
In a six-generation family with both essential tremor and
Parkinson disease, we identified a rare missense mutation of
HTRA2 as the causative allele. Family members homozygous for
this allele were more severely affected than those heterozy-
gous for this allele. The same mutation had been associated
with Parkinson characteristics in mouse mutants and with Par-
kinson disease in some, but not all, epidemiologic studies. Our
results suggest that HTRA2 may be responsible for essential
tremor in some families and that homozygosity for damaging
alleles of HTRA2 may be responsible for Parkinson disease.
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Based on these criteria, 11 relatives were diagnosed with es-
sential tremor and five relatives were diagnosed with essential
tremor coexisting with Parkinson disease (Table 1). All five
relatives with both essential tremor and Parkinson disease
reported having tremors for multiple years before appearance
of clinically apparent Parkinson signs (Table S1). In the family
as a whole, ages of onset of tremor ranged from approximately
10 to 60 y, although some family members were not able to
determine the exact age of onset as their tremor developed over
many years.
Gene Discovery. To identify the gene responsible for essential
tremor in the family, we carried out whole exome sequencing of
three severely affected relatives, IV:3, IV:4, and VI:5 (Table S2
and Fig. S1). Given that the kindred include multiple consan-
guineous marriages, we first considered the possibility of reces-
sive inheritance of essential tremor as the result of homozygosity
for a critical mutation that was identical by descent from a com-
mon ancestor. To evaluate this possibility, we identified homo-
zygous genomic regions greater than 1 MB shared by the three
affected relatives. There were three such regions, on chromosomes
2p13.1-p12, 14q32.13, and 22q11 (Table S3). We then identified, in
Fig. 1. Pedigree of family ET-1 segregating essential tremor, with genotypes at HTRA2 p.G399S. Individuals with essential tremor (ET) are shown with black
symbols, and those with Parkinson disease (PD) with red symbols. Age at onset of tremor for affected individuals, current ages, and genotypes at HTRA2
p.G399S are indicated in this order under the symbols. N indicates the wild-type allele, glycine; V indicates the variant allele, serine, at HTRA2 p.G399S.
Individuals who underwent exome sequencing (IV:3, IV:4, VI:5) are indicated with arrows. Subject VI:1, who is unaffected and heterozygous for HTRA2
p.G399S, is presently 37 y old, younger than the mean age at onset of essential tremor among heterozygotes in the family. Phenotypes of four relatives are
unknown: I:1, I:2, and III:1 are deceased, and V:11 refused clinical examination.
Table 1. Clinical diagnosis of individuals of family ET-1
Individual Age at onset of tremor Age at examination Essential tremor Parkinson disease
III:5 50 78 Severe No
IV:2 40 79 Severe Yes
IV:3 <30 81 Severe Yes
IV:4 <30 89 Severe Yes
IV:8 40 81 Severe Yes
IV:13 59 67 Severe No
IV:18 10 45 Severe No
V:3 48 56 Mild No
V:4 30 61 Mild No
V:6 50 60 Mild No
V:7 <55 59 Mild No
V:8 12 50 Severe No
V:9 15 56 Severe Yes
VI:5 10 25 Severe No
See Table S1 for detailed clinical characteristics.
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each of these regions, all variants predicted to be damaging
(Methods). The only potentially damaging variant was HTRA2
(high temperature requirement protein A2) p.G399S (c.1195G >
A, NM_013247) at chr2:74,759,825 G > A (rs72470545). HTRA2 p.
G399S was predicted to be damaging by bioinformatics prediction
tools Polyphen2 (score 0.986), SIFT (P = 0.02), and Muta-
tionAssessor (score 2.39).
We next genotyped HTRA2 p.G399S in all family members.
Of the 16 individuals with essential tremor in the family, five
were homozygous and 11 were heterozygous for the variant (Fig. 1).
The occurrence of both heterozygotes and homozygotes for the
mutation among affected relatives precluded recessive inheritance
via identity by descent. However, genotypes of the family were
consistent with dominant inheritance of essential tremor due to
this allele, possibly with a dosage effect.
To evaluate the kindred for the possibility of dominant in-
heritance of any mutation in the genome, we next identified all
potentially damaging variants, whether heterozygous or homozy-
gous, shared by the three affected relatives with exome sequence.
Including HTRA2 p.G399S, there were 13 such variants, all
missenses (Table S4). We genotyped all 13 variants in all family
members. The only variant segregating with essential tremor in
the family was the HTRA2 allele (Fig. 1 and Table S4). The
logarithm of odds (LOD) score for linkage of HTRA2 p.G399S
under an autosomal dominant model of inheritance was 5.27.
We next considered the possibility that affected family members
heterozygous for HTRA2 p.G399S might carry a second damaging
allele of HTRA2 on their other copy of chromosome 2. To eval-
uate this possibility, two tests were carried out. First, HTRA2 was
fully sequenced in all family members. No rare variants other than
p.G399S were identified. Second, to test the possibility of a critical
noncoding regulatory mutation of HTRA2 shared by affected
family members, extended (3.7 mb) haplotypes flanking HTRA2
were determined for all relatives by using informative polymorphic
markers (Fig. S2). Subjects heterozygous for HTRA2 p.G399S
did not share a second haplotype. We concluded that the pos-
sibility of a second pathogenic HTRA2 allele segregating in this
family is extremely unlikely. We also evaluated and excluded the
possibility of linkage of essential tremor to a mutation in any of
the genomic regions previously reported to be associated with
the disorder (Fig. S3).
Several lines of evidence suggested that the number of copies of
HTRA2 p.G399S influenced severity of the phenotype. First,
results of the Archimedes spiral test (17) suggested that severity of
action tremor was influenced by both genotype and age (Fig. 2).
Second, homozygosity versus heterozygosity at HTRA2 p.G399S
was significantly associated with age at onset of tremor [F = 28.99
(2, 24 df), P < 0.0001; Fig. 3A]. Mean ages at onset of tremor were
21.4 y and 41.3 y for subjects homozygous and heterozygous for
the mutation, respectively. Third, homozygosity versus heterozy-
gosity at HTRA2 p.G399S was associated with severity of both
postural tremor [F = 18.68 (2, 17 df)], P < 0.0001; Fig. 3B) and
kinetic tremor [F = 9.24 (2, 17 df)], P = 0.0019; Fig. 3C).
Of 59 other Turkish individuals with Parkinson Disease, none
carries HTRA2 p.G399S. In 25 other Turkish families, each in-
cluding multiple relatives with essential tremor, complete se-
quencing of HTRA2 did not reveal any damaging mutations. Of
364 unrelated Turkish controls, two were heterozygous and none
were homozygous for HTRA2 p.G399S, yielding an allele fre-
quency of 0.0027 for this population. The reported allele fre-
quency among persons of various ancestries is ∼0.0034 (Table
S4). Of the two Turkish controls heterozygous for the allele, one
was anonymous and the other had given permission to be
recontacted. The recontacted control is presently 27 y old. Upon
neurological examination, she had no signs of essential tremor.
Discussion
Whole exome sequencing of three severely affected relatives of
family ET-1, with no prior hypothesis about a causal gene,
revealed HTRA2 p.G399S as the only potentially damaging allele
cosegregating with essential tremor in the extended kindred.
Homozygosity versus heterozygosity for this allele was associated
with earlier age at onset and increased severity of essential tremor.
Homozygotes for the mutation expressed a more severe pheno-
type, including signs of Parkinson disease at middle age, sug-
gesting a dosage effect for this allele. Even among heterozygotes,
age at onset of tremor was variable, due to genetic or environ-
mental modifiers or stochastic effects (18).
HTRA2 encodes a serine protease of 458 aa that localizes to
the intermembrane space of mitochondria (19). Upon an apo-
ptotic stimulus, the HTRA2 protein is released from the mito-
chondria into the cytosol and binds to inhibitor-of-apoptosis
proteins to initiate apoptosis (19). HTRA2 proteolytic activity
also triggers caspase-independent cell death (20).
Several lines of evidence suggest involvement of HTRA2 in
Parkinson disease. In the mnd2 mouse model, HtrA2 p.S275C
leads to loss of protease activity and to a motor neuron degen-
eration phenotype with ataxia, repetitive movements, and akinesis
(21). In addition, HtrA2 knockout mice show parkinsonian fea-
tures due to the loss of neurons in striatum (22). Based on these
Fig. 2. Archimedes spiral tests of individuals of various ages and genotypes at HTRA2 p.G399S. For all individuals, R was the dominant right hand and L was
the nondominant left hand.






observations, Strauss et al. sequenced HTRA2 in a series of Par-
kinson disease patients and controls from Germany, and identified
HTRA2 p.G399S (the mutation of family ET-1) and HTRA2
p.A141S as associated with the disorder (Fig. 4A) (23). They also
identified HTRA2 in Lewy bodies of Parkinson disease patients
(23). Their study suggested that HTRA2 p.G399S leads to loss of
function, because both missense mutations (HTRA2 p.G399S and
HTRA2 p.A141S) led to mitochondrial dysfunction, altered mi-
tochondrial morphology, and decreased protease activity, and
HTRA2 p.G399S resulted in increased sensitivity to toxicity (23).
A recent study of transgenic mice also suggested that HtrA2
p.G399S is a loss-of-function allele, because mice overexpressing
a wild-type allele of HtrA2 showed significant motor impairments,
whereas mice overexpressing HtrA2 p.G399S had normal motor
function (24).
To experimentally evaluate a dosage effect for this allele, it
would be ideal to compare animal models heterozygous and ho-
mozygous for HtrA2 p.G399S. These animals have not been de-
veloped, but a clue to a possible dosage effect appears from the
comparison of wild-type, HtrA2+/−, and HtrA2−/− mice (22).
Compared with wild-type mice, HtrA2+/− mice appear to show
a subtle, although not statistically significant, decrease in perfor-
mance on sensory-motor tests (22). Increasing the number of
HtrA2+/−mice in these experiments and extending their evaluation
over a wider age range would provide valuable information on the
possibility of a dosage effect forHTRA2 loss-of-function mutations.
Three other rare missense alleles, HTRA2 p.R36W, p.P143A,
and p.R404W, have been reported in patients with Parkinson
disease (Fig. 4A) (25–27). HTRA2 p.A141S and p.P143A lie in
close proximity to serine at residue 142, which is phosphorylated
upon the activity of p38, dependent on PTEN-induced-putative-
kinase (PINK1) (Fig. 4B) (28, 29). HTRA2 p.G399S and
p.R404W lie in close proximity to serine at residue 400, which is
phosphorylated upon activation of cyclin-dependent kinase-5
(CDK5) (28, 29). In transgenic mice expressing HtrA2 p.G399S
in cortex, phosphorylation at residue 400 was significantly re-
duced (29). Phosphorylation of HTRA2 at both sites is impor-
tant for cellular stress response (29). Furthermore, PINK1 and
Fig. 3. Relationship between HTRA2 genotype and age at onset of essential
tremor and severity of tremors. V indicates the variant allele serine, and N
indicates the wild-type allele glycine at HTRA2 p.G399S. Subjects heterozy-
gous for the variant allele are indicated NV, and those homozygous for the
variant allele are indicated VV. (A) Essential tremor age at onset varies sig-
nificantly by genotype, P < 0.0001. (B) Severity of postural tremor of ho-
mozygous and heterozygous subjects differs significantly; analysis of
covariance by genotype with age at examination as covariate yields F =
18.68, (2, 17 df), P < 0.0001. (C) Severity of kinetic tremor of homozygous
and heterozygous subjects differs significantly; analysis of covariance by
genotype with age at examination as covariate yields F = 9.24, (2, 17 df), P =
0.0019. Individuals with NN genotype and +1 postural or kinetic tremor
scores did not fulfill the criteria for essential tremor diagnosis.
Fig. 4. Schematic representation of the HTRA2 protein and its activation
against mitochondrial stress. (A) Locations of all reported mutations in
HTRA2 in persons with essential tremor or Parkinson disease. The full-length
HTRA2 protein consists of a transmembrane domain (TM; residues 105–124),
a conserved catalytic trypsin-like serine protease domain (Tryp_SPc; residues
178–342), and a C-terminal PDZ domain (residues 363–445). Phosphorylation
sites are at Ser142 and Ser400. (B) Oxidative stress results in the activation of
p38 stress kinase pathway. In HTRA2, p38 phosphorylates serine at residue
142 in a PINK1-dependent manner; CDK5 phosphorylates serine at residue
400, increasing the proteolytic activity of HTRA2. Active HTRA2 induces
stress-responsive caspases. PINK1 also recruits Parkin, an E3 ubiquitin protein
ligase, from cytosol to mitochondria to induce mitophagy. Red diamonds
represent phosphorylation sites at residues 142 and 400. P, phosphorylation.
Adapted by permission from Macmillan Publishers Ltd: Nature Cell Biology
(20), copyright (2007).
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CDK5 kinases are both known to be associated with Parkinson
disease (30, 31). However, despite the biological plausibility of
a role for HTRA2 in Parkinson disease, subsequent epidemio-
logic studies did not detect higher frequencies of any of the rare
missense alleles of HTRA2 among Parkinson disease patients
than among controls (25–27, 32).
The role of HTRA2 in essential tremor may resolve this par-
adox. The individuals in family ET-1 who developed features of
Parkinson disease exhibited these symptoms decades after onset
of essential tremor. These subjects included all three individuals
homozygous for HTRA2 p.G399S and older than age 55, and
two individuals heterozygous for HTRA2 p.G399S and older
than age 78. These observations suggest that HTRA2 has a causal
role in essential tremor and in the subset of Parkinson disease
preceded by essential tremor. Among essential tremor patients
generally, the incidence of Parkinson disease is increased four- to
fivefold, and essential tremor and Parkinson disease have been
observed in the same families (33–35). We speculate that case-
control studies of that subset of Parkinson disease preceded by
essential tremor would reveal associations with functional mis-
sense alleles of HTRA2.
Although essential tremor is one of the most common inherited
neurologic disorders, identifying the responsible underlying genes
has been challenging. Complexities of essential tremor include
genetic heterogeneity, age-dependent penetrance, and variable
expressivity, leading to difficulties both in differential diagnosis and
in genetic analysis (18). Our results suggest that mutation of
HTRA2 can be responsible for essential tremor in some families
and that parkinsonian features may develop in these patients, after
age 70 in heterozygotes and in middle age in homozygotes. These
observations reveal one cause of essential tremor and may illumi-
nate some of the shared features of essential tremor and Parkinson
disease phenotypes.
Methods
Subjects. Family ET-1 is of Turkish origin. The proband was first evaluated at
Ankara University Medical School. He and his informative relatives were
followed at Ankara University Medical School and Hacettepe University
Medical School. This project was approved by the ethics committees of all
participating universities, and informed consent was obtained from all
individuals. Each participant was examined for essential tremor by using the
criteria of both the Washington Heights-Inwood Genetic Study of Essential
Tremor and the Consensus Statement of the Movement Disorder Society on
Tremor (Table 1 and Table S1) (15, 17). Each participant was rated for rest
and postural tremors and was asked to perform four different tasks (pouring
water, drinking water from a cup, finger-to-nose movement, and drawing
spirals) to elicit kinetic tremor. During the examination, severity of tremor
was rated during each task (17). Participants were evaluated for features of
Parkinson disease by using the diagnostic criteria of the UK Parkinson Dis-
ease Society Brain Bank (16). Diagnosis of Parkinson disease required pres-
ence of bradykinesia plus at least one of muscular rigidity, resting tremor, or
postural instability (16). We collected histories about distribution and se-
verity of tremor and change of these parameters over time. Participants
were interviewed about concurrent use of drugs that might cause action or
resting tremor and for symptoms of hyperthyroidism, which was ruled out
by thyroid-stimulating hormone tests as needed. Clinical assessments were
carried out by at least two neurologists without knowledge of participants’
genotypes. An additional 25 families with hereditary essential tremor, 59
patients with Parkinson disease, and 364 healthy controls, ages 20–30 and
from the same central Anatolian region as family ET-1, were recruited for
genetic analysis from Ankara University Medical School, Hacettepe University
Medical School, and Bilkent University. Unaffected individuals showed no signs
of disease at the time of examination. Because controls were young adults,
they serve as population controls. DNA was extracted from blood by using
Nucleospin Blood Kit (Macherey-Nagel) according to manufacturer’s protocol.
Genomics. Three severely affected individuals were selected for whole exome
sequencing. Library construction and sequencing was carried out as described
(36). Isolated genomic DNA was randomly sheared into 200–300 bp followed
by end repair, A-tailing, and indexed paired-end adapter ligation. Exomes
were captured by SeqCap EZ Exome v2 (Roche) and hybridized to biotinylated
capture probes. Libraries were sequenced on an Illumina HiSeq2500.
Bioinformatics. Paired-end sequence reads were aligned to the human ref-
erence genome (hg19) by using Burrows-Wheeler Aligner (v0.6.1-r104) (37).
Removal of PCR duplicates, sorting, and indexing were done by using
SAMtools v0.1.18 (38). Indel realignments and base quality score recalibra-
tion were done with Genome Analysis Tool Kit (GATK; v3.0–0-g6bad1c6;
broadinstitute.org/gatk) by using recommended parameters (39). Genotypes
were called and filtered by using GATK Unified Genotyper and Variant Fil-
tration tools. Variants were annotated by using our in-house pipeline.
Common SNPs and artifacts were excluded by using dbSNP v138, the Na-
tional Heart, Lung, and Blood Institute (NHLBI) Exome Sequencing Project
(evs.gs.washington.edu/EVS), the 1000 Genomes Project (1000genomes.org),
and 700 exomes previously sequenced in our laboratory. Variants were de-
fined as potentially damaging if they led to a premature stop codon or were
missense mutations with scores on in silico prediction tools of SIFT P ≤ 0.05,
PolyPhen2 ≥ 0.8, and MutationAssessor ≥ 1.95 (Table S4) (sift.jcvi.org;
genetics.bwh.harvard.edu/pph2; mutationassessor.org) (40–42).
Sanger Sequencing. Genotypes for candidate variants for 24 informative
relatives of family ET-1 were determined by capillary sequencing (ABI 3130xl
Genetic Analyzer). All coding regions, potential regulatory regions, and
miRNA binding sites of HTRA2 were sequenced in probands from 25 un-
related families with multiple relatives with essential tremor. Primers were
designed by using Primer3 (Table S5) (43). Products were analyzed via gel
electrophoresis and Sanger sequenced. Sanger traces were analyzed with
CLCBio Main Workbench software package (CLCBio). TaqMan genotyping
assays (Life Technologies) were used for screening HTRA2 p.G399S in Parkinson
disease patients and controls (ABI 7900HT Fast Real-Time PCR System).
Family ET-1 was genotyped with FAM- and HEX-labeled primers for poly-
morphic markers on chromosome 2 flanking HTRA2 (ABI 3130xl Genetic
Analyzer). Data were analyzed with GeneMapper v4.0 software package
(Applied Biosystems).
Linkage Analysis. A LOD score for linkage of HTRA2 to essential tremor in the
ET-1 family was calculated by using LINKAGE v6.0 (44) under an autosomal
dominant mode of inheritance with penetrance for homozygous or hetero-
zygous genotypes of 1.0 at age 40 and older and 0.6 before age 40, no
phenocopies, and a mutant allele frequency of 0.01 in the general population.
Statistical Analysis. Statistical significance was evaluated by one-way analysis
of variance, or analysis of covariance, as appropriate.
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